Recent published study showed that health care providers may lack the knowledge to diagnose and even treat prediabetes.

Treatment of hypoglycemia contributes to ASCVD risk reduction.

A person cannot be denied health care coverage and benefits because they have diabetes prior to employment.

T1D patients with certain characteristics would benefit the most from reimbursement of blood glucose test strips.

David Kliff from Diabetes Investor adds his thoughts about what is happening in the diabetes marketplace.

At her last visit, your patient’s labs showed a eGFR 55 ml/min/1.73 m2. At this visit, her labs measured an eGFR of 44 ml/min/1.73 m2. Dose reduction/cessation should be considered for all of the following agents EXCEPT: A. Glyburide B. Sitaglipitin C. Metformin D. Pioglitazone Follow the link for the correct answer.

What percentage of your prediabetes patients do you recommend a pharmaceutical treatment? 1. 10-25% 2. 25-50% 3. Greater than 50% 4. Zero. I only recommend diet and exercise. Follow the link to share your response.

Dr. Leigh Perreault is an associate professor of medicine, physician and clinical researcher at the University of Colorado Denver School of Medicine, Aurora, CO. Her overarching research interest lies in understanding the different pathways by which people develop type 2 diabetes, and developing tailored strategies for diabetes prevention. Complementing her independent research interests, Dr. Perreault works closely with collaborators examining emerging risk factors for diabetes such as sleep restriction, intramuscular lipids and the human microbiome.

In this Exclusive Interview, Dr. Leigh Perreault talks with Diabetes in Control Medical Editor Joy Pape during the ADA meeting in San Diego, California, about obesity and the effects of the human microbiome on this disease.

Dr. Leigh Perreault discusses the genetic and environmental aspects of obesity, and the role of the human microbiome in obesity.